Advanced Search
WU Tao, WANG Xiumei, ZHU Liping, FU Lati, OU Jianghua, NI Duo. Analysis on Related Factors of Bone Mineral Density Reduction in Postmenopausal Women with Early Breast Cancer One Year after Surgery[J]. Cancer Research on Prevention and Treatment, 2013, 40(10): 966-968. DOI: 10.3971/j.issn.1000-8578.2013.10.012
Citation: WU Tao, WANG Xiumei, ZHU Liping, FU Lati, OU Jianghua, NI Duo. Analysis on Related Factors of Bone Mineral Density Reduction in Postmenopausal Women with Early Breast Cancer One Year after Surgery[J]. Cancer Research on Prevention and Treatment, 2013, 40(10): 966-968. DOI: 10.3971/j.issn.1000-8578.2013.10.012

Analysis on Related Factors of Bone Mineral Density Reduction in Postmenopausal Women with Early Breast Cancer One Year after Surgery

More Information
  • Received Date: November 04, 2012
  • Revised Date: November 29, 2012
  • Objective To identify the related factors of bone mineral density reduction in postmenopausal women with early breast cancer 1 year after surgery. Methods The clinical data of 242 patients with early breast cancer of postmenopausal women in our hospital were collected and analyzed. Univariate and multivariate logistic regression model was used for analysis of related factors of bone mineral density reduction in postmenopausal women with breast cancer. Results Univariate logistic analysis on ten potential risk factors showed that age, BMI, Oral AI endocrine therapy, postmenopausal time and level of estradiol were signifi cant variables affecting bone mineral density reduction(P < 0.05). Multivariate logistic analysis showed that Oral AI endocrine therapy, long postmenopausal time and low level of estradiol were major risk factors( P < 0. 05). Conclusion Oral AI endocrine therapy, long postmenopausal time, low level of estradiol are major risk factors of bone mineral density reduction of postmenopausal women with early breast cancer. We should pay great attention to the patients with these risk factors and carry out appropriate treatment to decrease bone loss incidence.
  • [1]
    Abdel-Razeq H, Awidi A. Bone health in breast cancer survivors[J]. J Cancer Res Ther, 2011,7(3): 256-63.
    [2]
    Bryce J, Bauer M, Hadji P. Aromatase inhibitor-associated bone loss[J]. Oncol Nurs Forum, 2011, 38(3): 273-6.
    [3]
    Hadji P, Aapro MS, Body JJ, et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment[J]. Ann Oncol, 2011, 22(12): 2546-55.
    [4]
    Dawson-Huqhes B, Looker AC, Tosteson AN, et al. The potential impact of the national osteoporosis foundation guidance on treatment eligibility in the usa: an update in NHANES 2005-2008[J]. Osteoporos Int, 2012, 23(3): 811-20.
    [5]
    Liu ZH,Zhu HM,Yang DZ,et al. Recommendations of the diagnostic criteria for osteoporosis in chinese(2nd draft)[J]. Zhongguo Gu Zhi Shu Song Za Zhi,2000,6(1):1-3. [刘忠 厚,朱汉民,杨定焯,等.中国人骨质疏松症建议诊断标准 (第二稿)[J].中国骨质疏松杂志,2000,6(1):1-3.
    [6]
    Lester JE, Dodwell D, Horsman JM, et al. Current management of treatment-induced bone loss in women with breast cancer treated in the united kingdom[J]. Br J Cancer, 2006, 94(1):30-5.
    [7]
    Geisler J, Lønning PE. Aromatase inhibitors as adjuvant treatment of breast cancer[J]. Crit Rev Oncol Hematol, 2006, 57(1): 53-61.
    [8]
    Jin H, Tu D, Zhao N, et al. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover[J]. J Clin Oncol, 2012, 30(7): 718-21.
    [9]
    Lønning PE. Exploring the lack of cross-resistance between aromatase inhibitors: evidence for a difference?[J]. Anticancer Drugs, 2008, 19 Suppl 2:S11-3.
    [10]
    Lester JE, Dodwell D, Purohit OP, et al.Prevention of anastrozoleinduced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer[J]. Clin Cancer Res, 2008, 14(19): 6336-42.
    [11]
    Coleman R, Cook R, Hirsh V, et al. Zoledronic acid use in cancer patients: more than just supportive care?[J]. Cancer, 2011, 117(1): 11-23.
    [12]
    Kim JE, Ahn JH, Jung KH, et al. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the korean cancer study group (KCSG-BR06-01)[J]. Breast Cancer Res Treat, 125(1): 99-106.

Catalog

    Article views (1475) PDF downloads (770) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return